Escitalopram Neuroimaging Supplement

Inclusion Criteria: * male or female. * from 18-64 years of age. * right-handed, by virtue of assessment with the Edinburgh Handedness Inventory * capacity to render informed consent. * already enrolled in clinical study NCT00149799. * must be an outpatient with a primary (the condition that is most central to the patient's current distress) psychiatric diagnosis of BDD, as defined by DSM-IV criteria and by a BDD Yale-Brown Obsessive-Compulsive Scale Score greater than or equal to 24. Exclusion Criteria: * with serious medical illness or instability for which hospitalization may be likely within four months of entry into the study, or current renal insufficiency or diabetes. * any pregnant or lactating women or those of childbearing potential not using medically accepted forms of contraception will be excluded. Pregnancy status will be determined by administration of a blood beta-HCG test prior to each PET scan. * with recent or anticipated radiation exposure, which, combined with the exposure in the present study, will exceed allowable annual limits for the subject * with a history of hypersensitivity to any component of FDG * with specific comorbid psychiatric diagnoses (alcohol abuse or dependence within the past 3 months, bipolar disorder, psychosis, organic mental disorder, development disorder, borderline personality disorder, body image concerns accounted for primarily by an eating disorder or weight concerns). If subjects have another comorbid diagnosis, the BDD must be the primary concern. * MRI- incompatibilities (for example, metal implants, pacemakers)